Dr. Lyudmila A. Bazhenova

About Lyudmila A. Bazhenova

Education:

• Earned an MD from Nizhny Novgorod State Medical Academy, Russia.

Experience:

• Completed a Fellowship in Hematology and Oncology at Scripps Clinic, La Jolla, CA.
• Served a Residency in Internal Medicine at UCLA-VA Greater Los Angeles Healthcare System.
• Holds the position of Clinical Professor of Medicine at UC San Diego Moores Cancer Center.
• Acts as the Lung Cancer Unit Leader and Director of the Hematology Oncology Training Program at UC San Diego.
• Has over 15 years of experience in lung cancer management, emphasizing a multidisciplinary treatment approach and active clinical research involvement.

Area of expertise

Affiliated Hospitals

UC San Diego Moores Cancer Center

UC San Diego Medical Center - Hillcrest

Clinical Trials Lyudmila A. Bazhenova is currently running

Osimertinib + Bevacizumab

for Lung Cancer

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.

Recruiting2 awards Phase 331 criteria

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Recruiting2 awards Phase 328 criteria

More about Lyudmila A. Bazhenova

Other Doctors you might be interested in

Frequently asked questions